[go: up one dir, main page]

AR076401A1 - Bisaril alquinilamidas como moduladores alostericos negativos del receptor metabotropico de glutamato 5 (mglur5) - Google Patents

Bisaril alquinilamidas como moduladores alostericos negativos del receptor metabotropico de glutamato 5 (mglur5)

Info

Publication number
AR076401A1
AR076401A1 ARP100101367A ARP100101367A AR076401A1 AR 076401 A1 AR076401 A1 AR 076401A1 AR P100101367 A ARP100101367 A AR P100101367A AR P100101367 A ARP100101367 A AR P100101367A AR 076401 A1 AR076401 A1 AR 076401A1
Authority
AR
Argentina
Prior art keywords
alkyl
independently selected
halo
formula
aryl
Prior art date
Application number
ARP100101367A
Other languages
English (en)
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of AR076401A1 publication Critical patent/AR076401A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44Iso-indoles; Hydrogenated iso-indoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Composiciones farmacéuticas que contienen compuestos de formula 1, y el uso de compuestos de formula 1 para tratar enfermedades y trastornos que incluyen esquizofrenia, paranoia, depresion, enfermedad maníaco-depresiva y ansiedad. Reivindicacion 1: Un compuesto de formula 1, o una sal farmacéuticamente aceptable de los mismos, en la que cada uno de W1, W2, W3, W4, W5, X1, X2, X3, X4, Y y Z1, Z2, Z3, Z4 y Z5 se selecciona independientemente entre C, N, S y O; ------ es independientemente un enlace sencillo o un doble enlace; n es 1 o 2; m es 0 o 1; p es 1 o 2; cada uno de R1 y R2 se selecciona independientemente entre H, hidroxilo, halogeno, ciano, alquilo C1-6, halo-alquilo C1-6 y -O(alquilo C1-6); R3 se selecciona entre H, halogeno, alquilo C1-6, halo-alquilo C1-6, -O(alquilo C1-6), halo-alcoxi C1-6 e hidroxilo; cada uno de R4 y R5 se selecciona independientemente entre H, alquilo C1-6, cicloalquilo C3-6, arilo, heteroarilo, ariloxi, heteroariloxi, alquil C1-6-NR7R8, el grupo de formula (2) y los grupos alquilo C1-6, cicloalquilo C3-6, arilo, heteroarilo, ariloxi, heteroariloxi, alquil C1-6-NR7R8 y el grupo de formula (2) están opcionalmente sustituidos independientemente con 1 a 4 -alquilo C1-6, halo-alquilo C1-6, -OH o -NH2; o R4 y R5 y los átomos a los que están unidos forman un anillo; R6 es de 1 a 4 grupos, cada uno de ellos seleccionado independientemente entre H, halogeno, oxo, ciano, alquilo C1-6, halo-alquilo C1-6, -O(alquilo C1-6), heterociclilo, NO2 y amino; y cada uno de R7 y R8 se selecciona independientemente entre H, alquilo C1-6, arilo y R7 y R8 pueden tomarse junto con el nitrogeno al que están unidos para formar un heterociclo saturado que contiene 5-7 átomos seleccionados independientemente entre 0, N, O o S.
ARP100101367A 2009-04-23 2010-04-23 Bisaril alquinilamidas como moduladores alostericos negativos del receptor metabotropico de glutamato 5 (mglur5) AR076401A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17187809P 2009-04-23 2009-04-23

Publications (1)

Publication Number Publication Date
AR076401A1 true AR076401A1 (es) 2011-06-08

Family

ID=42212154

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100101367A AR076401A1 (es) 2009-04-23 2010-04-23 Bisaril alquinilamidas como moduladores alostericos negativos del receptor metabotropico de glutamato 5 (mglur5)

Country Status (3)

Country Link
US (1) US20100273772A1 (es)
AR (1) AR076401A1 (es)
WO (1) WO2010124047A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2634923C (en) 2005-12-23 2015-05-05 Ariad Pharmaceuticals, Inc. Acetylenic bicyclic heteroaryl compounds useful as kinase inhibitors
EA021781B1 (ru) * 2010-12-02 2015-08-31 Эли Лилли Энд Компани 3-замещенные 6-(пиридинилметокси)пирролопиридиновые соединения
US8853237B2 (en) * 2010-12-30 2014-10-07 Vanderbilt University Naphthyridinone analogs as mGluR5 positive allosteric modulators
NZ703537A (en) * 2012-10-18 2018-06-29 Hoffmann La Roche Ethynyl derivatives
CA3167093A1 (en) 2012-12-12 2014-06-12 Ariad Pharmaceuticals, Inc. Crystalline form c of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
JP6744218B2 (ja) 2013-11-15 2020-08-19 ザ ウィスター インスティテュート オブ アナトミー アンド バイオロジー Ebna1阻害剤およびそれらの使用方法
PT3087051T (pt) * 2013-12-24 2020-10-21 Oncotartis Inc Compostos de nicotinamida e benzamida e métodos para utilizar os mesmos
WO2016029454A1 (en) * 2014-08-29 2016-03-03 Merck Sharp & Dohme Corp. TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE
CN106146391A (zh) * 2015-04-15 2016-11-23 中国科学院上海药物研究所 5-芳香炔基取代的苯甲酰胺类化合物及其制备方法、药物组合物和用途
AU2016262572B2 (en) 2015-05-14 2020-04-30 The Wistar Institute Of Anatomy And Biology EBNA1 inhibitors and methods using same
HUE060914T2 (hu) * 2017-06-22 2023-04-28 Pfizer Dihidro-pirrolo-piridin származékok
TW201946919A (zh) 2018-05-17 2019-12-16 威斯塔研究所 Ebna1抑制劑晶形、其製備方法及其使用方法
KR20220014854A (ko) * 2020-07-29 2022-02-07 주식회사 비보존 mGluR5 및 5-HT2A 수용체의 이중 조절제 및 이의 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6593322B1 (en) * 1999-03-17 2003-07-15 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
US7488756B2 (en) * 2001-01-23 2009-02-10 Neurosearch A/S Use of non-competitive and selective GluR5 antagonists as glutamate receptor modulating compounds
JP2006513996A (ja) * 2002-10-24 2006-04-27 メルク エンド カムパニー インコーポレーテッド 代謝調節型グルタミン酸受容体結合用トレーサーとしてのアルキン誘導体
US8853392B2 (en) * 2007-06-03 2014-10-07 Vanderbilt University Benzamide mGluR5 positive allosteric modulators and methods of making and using same
AU2008271051C1 (en) * 2007-06-29 2012-10-04 Acucela Inc. Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders
US20090325964A1 (en) * 2008-05-23 2009-12-31 Wyeth Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression

Also Published As

Publication number Publication date
WO2010124047A1 (en) 2010-10-28
US20100273772A1 (en) 2010-10-28

Similar Documents

Publication Publication Date Title
AR076401A1 (es) Bisaril alquinilamidas como moduladores alostericos negativos del receptor metabotropico de glutamato 5 (mglur5)
PE20142081A1 (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos
AR079205A1 (es) Morfolinotiazoles como moduladores alostericos positivos alfa 7
AR083813A1 (es) Derivados de pirazol aminopirimidina como moduladores de lrrk2
CO6251271A2 (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR067757A1 (es) Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales.
AR082029A1 (es) Derivados de heterociclos nitrogenados, composiciones y metodos para modular la via de señalizacion de wnt
AR084553A1 (es) DERIVADOS IMIDAZOLICOS HETEROCICLICOS INHIBIDORES DE b-SECRETASA, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y USO DE LOS MISMOS PARA TRATAR ENFERMEDADES NEURODEGENERATIVAS, EN PARTICULAR ALZHEIMER
PE20151781A1 (es) Piridonamidas como moduladores de canales de sodio
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
AR074435A1 (es) Derivados de 1,3-benzotiazol, medicamentos que los contienen y uso de los mismos en el tratamiento del cancer.
AR078163A1 (es) Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes
AR061369A1 (es) Derivados de pirimidina y composiciones farmaceuticas que los comprenden
AR082889A1 (es) Compuestos y composiciones para la inhibicion de nampt
AR074608A1 (es) Derivados de 2-(piperidin-1-il)-4-heterociclil-tiazol-5-carboxilico para infecciones bacterianas
AR080596A1 (es) Compuestos alquilamido y composiciones farmaceuticas
BR112015015275A8 (pt) composto heterocíclico substituído por halogênio, antagonista do receptor de lpa, composição farmacêutica e uso
NI201000011A (es) Derivados de pirimidina 934.
AR078756A1 (es) Moduladores alostericos positivos (map)
PE20170682A1 (es) Derivados de pirimidina sustituidos con heterociclilo opcionalmente condensados utiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncologicas y autoinmunitarias
AR082111A1 (es) Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas
AR067648A1 (es) Derivados de 2-aza-biciclo [2,2,2]octano, uso de los mismos y composiciones farmaceuticas que los contienen
CO6230982A2 (es) Compuestos triciclicos que contienen actividad antagonista de factor de liberacion de corticotropina y composiciones farmaceuticas que los contienen
AR067075A1 (es) Derivados de isoxasol - imidazol

Legal Events

Date Code Title Description
FA Abandonment or withdrawal